Platelet-activating factor (PAF) is a phospholipid which induces platelet aggregation and triggers the release reaction by a mechanism that is different from those of both adenosine diphosphate (ADP) and arachidonic acid (AA). Recent published data suggest that endogenous PAF from platelets may account for that part of thrombin, collagen and ionophore A23187 induced aggregation which is not prevented by blocking the ADP and AA mechanisms, but which is diminished by phospholipase A2 inhibitors. Thus a clear understanding of its mode of formation, its effects on platelets and other cells and its subsequent metabolism should lead to the development of rationales for the prevention of thrombotic episodes.
The specific aims of this proposal are (1) to determine whether an arachidonic acid containing alkyl ether phospholipid is present in human platelets and if so, how it is changed in response to thrombin and collagen, (2) to determine basal levels of lyso-PAF in human platelets by its chemical conversion of PAF and quantitation by radioimmunoassay after purification by HPLC, (3) to develop a radioimmunoassay for PAF, (4) to evaluate the platelet aggregating activity of PAF analogs containing saturated and unsaturated fatty acids at 2-position of PAF.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Unknown (R23)
Project #
5R23HL030964-03
Application #
3448546
Study Section
Hematology Subcommittee 2 (HEM)
Project Start
1983-07-01
Project End
1986-06-30
Budget Start
1985-07-01
Budget End
1986-06-30
Support Year
3
Fiscal Year
1985
Total Cost
Indirect Cost
Name
Thomas Jefferson University
Department
Type
Schools of Medicine
DUNS #
061197161
City
Philadelphia
State
PA
Country
United States
Zip Code
19107